2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2028

Medication Adherence and Quality of Life in Children with Rheumatic Disease
Abstract Number: 387

Medication Choices and Medication Survival in a National Multicentre Community Based Rheumatoid Arthritis Cohort
Abstract Number: 512

Memory B Cell Phenotypic and Gene Expression Profiling in Primary Sjogren’s Syndrome: Implications for Disease Diagnosis
Abstract Number: 156

Menopause and the Prevalence of Gout and Hyperuricemia: An Age-Matched Case Control Study
Abstract Number: 3

Mesenchymal Stem Cells Differentiate Into Osteoblasts in Response to Inflammation
Abstract Number: 257

Meta-Analysis of Four 12-Week Phase III Clinical Trials Investigating the Effect of TDT 064, a Transdermal Gel, in Osteoarthritis of the Knee
Abstract Number: 1697

Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Abstract Number: 352

Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis
Abstract Number: 355

Metaanalysis of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Transformylase (ATIC) 347C>G Polymorphism Affecting Methotrexate Efficacy and Toxicity in Rheumatoid Arthritis Patients
Abstract Number: 2665

Metabolic Reprogramming of Autoimmune T Cells in Rheumatoid Arthritis
Abstract Number: 2253

Metabolic Syndrome Is Not Only a Risk Factor for Cardiovascular Events in Systemic Lupus Erythematosus but Also Associated with Cumulative Organ Damage: A Cross-Sectional Analysis of 311 Patients
Abstract Number: 162

Metabolic Syndrome: The Genesis of Nephrolithiasis in Gout Patients
Abstract Number: 1095

Metal Concentrations in Patients with Failed Metal-On-Metal Hip Prostheses Determine the Inflammatory Phenotype in Peri-Implant Tissue
Abstract Number: 924

Methods to Link a U.S. Arthritis Cohort with Medicare Administrative Claims Data
Abstract Number: 2640

Methotrexate Adverse Events in a Cohort of US Veterans with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].